Antigenic selection and the associated process of V gene hypermutation have a major influence on the antibody repertoire. These processes act at a stage in B-cell development also critical for the most common forms of human lymphomas. This project characterizes the corresponding cellular and molecular processes using two unique experimental systems developed in the previous grant period. A viral antigen, HIV gp120, was found to selectively bind and activate a large B-cell subset through conserved sequences expressed by the VH3 Ig gene family, through apparent interaction with novel non-CDR framework sites. During clinical HIV infection, the VH3 B-cell population is initially expanded and activated, followed by a selective clonal deletion paralleling the loss of CD4 T cells. These findings can be conceptualized as a precedent for superantigens of the B-cell lineage. The corollary of this concept is that the biologic disturbance of gp120- binding B-cell clones may be an important factor in the humoral immune dysfunction and elevated risk of B-cell lymphomagenesis in these individuals. In the proposed project, we will first define the structural basis of the gp120-VH3 Ig interaction. The antibody motifs and gp120 epitopes required for binding will be defined, and selective peptide or protein antagonists of this interaction will be generated. Second, we will determine the cell biologic processes accounting for HIV- induced VH3 B-cell depletion. We will define their direct response to gp120, and the effectiveness of candidate VH3 depletion mechanisms. Third, we will evaluate the potential role of this superantigen interaction in HIV-associated lymphomagenesis by testing the prevalence of this VH3 Ig subset among HIV-associated versus sporadic lymphomas. A real-time assay for V gene hypermutation has been developed, based on a gene-specific PCR DNA repair assay which detects mutational activity in endogenous Ig VDJ segments of primary B-cells or cell lines. Our studies reflect the predominance of a gene conversion process which is selectively active in a sequence and stage-specific manner for VDJ segments in hypermutation-positive (germinal center) B cells. In the proposed work, our first goal is to ascertain the structural features of these events by genomic isolation and characterization of the gene conversion tracks and candidate donor genes. Second, the primary cell assay will be manipulated with enzyme specific inhibitors and a panel of immunologic stimuli to search for predominant biochemical and cell physiologic processes which may activate or silence V gene conversion. Third, the hypermutation assay will be used to screen and characterize germinal center B-cell lines with constitutive or inducible hypermutation activity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA012800-22
Application #
3728672
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
22
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Sandusky, H; Cilluffo, M; Braun, J et al. (2001) Ocular pANCA antigens are expressed in nonpigmented ciliary body epithelium and are conserved in multiple mammalian species. Ocul Immunol Inflamm 9:25-34
Wang, C X; Wadehra, M; Fisk, B C et al. (2001) Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. Blood 97:3890-5
Gordon, M S; Kato, R M; Lansigan, F et al. (2000) Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells. Proc Natl Acad Sci U S A 97:5504-9
Wang, C X; Fisk, B C; Wadehra, M et al. (2000) Overexpression of murine fizzy-related (fzr) increases natural killer cell-mediated cell death and suppresses tumor growth. Blood 96:259-63
Sutton, C L; Yang, H; Li, Z et al. (2000) Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 46:58-63
Neshat, M N; Goodglick, L; Lim, K et al. (2000) Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig. Int Immunol 12:305-12
Gordon, L K; Eggena, M; Targan, S R et al. (2000) Mast cell and neuroendocrine cytoplasmic autoantigen(s) detected by monoclonal pANCA antibodies. Clin Immunol 94:42-50
Malone, C S; Patrone, L; Buchanan, K L et al. (2000) An upstream Oct-1- and Oct-2-binding silencer governs B29 (Ig beta) gene expression. J Immunol 164:2550-6
Yamashita, Y; Oritani, K; Miyoshi, E K et al. (1999) Syndecan-4 is expressed by B lineage lymphocytes and can transmit a signal for formation of dendritic processes. J Immunol 162:5940-8
Thompson, A A; Do, H N; Saxon, A et al. (1999) Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia. Leuk Lymphoma 32:561-9

Showing the most recent 10 out of 153 publications